CDA | Evidence Driven
CDA | Evidence Driven

donanemab

Details

Generic Name:
donanemab
Project Status:
Pending
Therapeutic Area:
Alzheimer disease
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0857-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Donanemab is indicated for the treatment of Alzheimer's disease. Treatment with donanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. In controlled clinical trials, donanemab was found to slow the decline in cognition and function in a clinically meaningful manner and demonstrated significant amyloid plaque removal.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Donanemab is indicated for the treatment of Alzheimer's disease. Treatment with donanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. In controlled clinical trials, donanemab was found to slow the decline in cognition and function in a clinically meaningful manner and demonstrated significant amyloid plaque removal.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : June 19, 2024